+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Embolotherapy - Global Strategic Business Report

  • PDF Icon

    Report

  • 282 Pages
  • June 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5302702
The global market for Embolotherapy was estimated at US$3.3 Billion in 2025 and is projected to reach US$5.3 Billion by 2032, growing at a CAGR of 7.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Embolotherapy Market - Key Trends & Drivers Summarized

How Is Embolotherapy Revolutionizing Minimally Invasive Treatments?

Embolotherapy, a cutting-edge minimally invasive procedure, is redefining the landscape of medical treatments by effectively blocking blood flow to targeted areas, facilitating treatment for a variety of complex conditions such as cancer, vascular anomalies, and trauma-related bleeding. Initially employed to manage gastrointestinal bleeding and traumatic injuries, embolotherapy has evolved significantly, with applications expanding to fields like oncology and women’s health. In oncology, transarterial chemoembolization (TACE) and radioembolization are widely used for liver cancer treatment, depriving tumors of blood supply while delivering localized chemotherapy, minimizing damage to surrounding tissues. Similarly, uterine fibroid embolization has emerged as a preferred alternative to hysterectomy for women seeking non-surgical solutions, offering a less invasive, quicker recovery pathway. Beyond these areas, embolotherapy has become a popular choice in treating varicose veins, managing arterial malformations, and controlling bleeding in emergency trauma cases, providing healthcare providers with an efficient and often life-saving option in complex scenarios.

Beyond its primary applications, embolotherapy is recognized for its ability to manage high-risk patients who may not be ideal candidates for traditional surgical procedures. With its minimally invasive nature, the procedure reduces the overall risk of complications, shortens hospital stays, and decreases recovery time, factors that resonate with patient preferences for treatment. The procedure’s versatility allows it to be tailored to individual patients’ needs, whether in outpatient settings or within intensive care environments, which has broadened its appeal among healthcare providers. Additionally, in trauma cases, embolotherapy’s rapid deployment and precision in controlling internal bleeding can stabilize patients for further interventions. Given these benefits, embolotherapy continues to be a pivotal technique within interventional radiology and is projected to play an increasingly prominent role in managing complex medical conditions with a focus on patient-centered care.

What Technological Advancements Are Propelling Embolotherapy Forward?

Recent technological breakthroughs in imaging and catheter systems are propelling embolotherapy to new heights, making procedures safer, more precise, and increasingly effective across various clinical settings. Imaging advancements, such as high-definition fluoroscopy, MRI-guided intervention, and 3D imaging, allow healthcare providers to visualize target areas with remarkable detail, ensuring embolic agents are precisely deployed and minimizing impact on surrounding healthy tissue. Alongside these imaging enhancements, embolic materials themselves have evolved, with innovative options like drug-eluting beads and biodegradable microspheres offering dual benefits. These advanced materials block blood flow while simultaneously delivering localized drug therapy over time, enabling a more comprehensive approach to treating tumors and other complex conditions. The combination of imaging technology and advanced materials significantly enhances patient outcomes and broadens the potential applications of embolotherapy.

Another key development is the evolution of catheter technology, with new designs in micro and steerable catheters improving navigation within intricate vascular networks. This level of control is essential in procedures requiring pinpoint accuracy, such as those targeting tumors or abnormal blood vessels in sensitive areas like the brain. Additionally, robotic-assisted embolotherapy is an emerging trend, allowing clinicians to perform complex procedures with increased precision and reduced radiation exposure. The integration of artificial intelligence (AI) and machine learning in embolotherapy is also on the horizon, offering predictive insights into procedure outcomes, which can guide customized treatment plans. Collectively, these technological advancements are transforming embolotherapy into a highly precise, effective treatment option, meeting the evolving demands of modern healthcare and expanding the possibilities for minimally invasive interventions.

Why Are New End-Use Applications for Embolotherapy Emerging?

The scope of embolotherapy is rapidly expanding across a variety of therapeutic areas, largely due to its minimally invasive nature and effectiveness in treating hard-to-reach conditions. In oncology, for example, the procedure has proven effective not only for liver cancer but also for renal, prostate, and other types of tumors, offering patients less invasive alternatives to traditional surgery with fewer side effects. This technique is also becoming more common in trauma care, where its capacity to control internal bleeding makes it a critical tool in stabilizing patients before other surgical interventions. In women’s health, embolotherapy is gaining traction with procedures like uterine fibroid embolization, providing a non-surgical solution that appeals to patients seeking alternatives to hysterectomy, with quicker recovery times and less risk involved. These applications highlight embolotherapy’s potential to become a cornerstone treatment in multiple medical fields.

The versatility of embolotherapy extends to cardiovascular applications, where it is used to treat arteriovenous malformations (AVMs) and prevent aneurysms by regulating abnormal blood flow. As personalized medicine continues to grow, the procedure's adaptability enables it to align with patient-specific needs, offering the possibility of combining embolic agents with targeted therapies. This personalized approach is expected to support further expansion in treatment areas, as clinicians can tailor procedures to individual patient profiles. Additionally, embolotherapy is seeing applications in gastrointestinal and urological treatments, as its precision and minimal invasiveness make it suitable for delicate structures. The broader adoption of this technique is not only improving patient outcomes but also enabling healthcare providers to offer advanced treatment options across an increasing array of medical conditions, reinforcing embolotherapy’s role as a critical tool in modern interventional medicine.

What’s Driving the Growth of the Global Embolotherapy Market?

The growth in the embolotherapy market is driven by several factors, primarily rooted in technological advancements, expanding end-use applications, and evolving healthcare preferences. Technological innovations such as high-definition imaging and sophisticated catheter designs have enhanced procedural precision, making embolotherapy a reliable choice across various therapeutic fields. This is particularly relevant in oncology, where the procedure’s minimally invasive nature and effectiveness in tumor targeting have led to increased adoption, especially in cases of liver and renal cancers. Furthermore, the development of drug-eluting and biodegradable embolic agents has broadened the scope of treatments, allowing for dual-action approaches that block blood supply and deliver localized drug therapy, a feature gaining traction in the oncology sector.

End-use expansion also plays a significant role in market growth, with embolotherapy being increasingly used in trauma care, women's health, cardiovascular applications, and even emerging fields like urology and gastroenterology. Additionally, the trend towards patient-centered healthcare and the growing demand for minimally invasive procedures are further fueling adoption, as patients increasingly seek alternatives with shorter recovery times and lower complication risks. An aging population and rising incidence of chronic diseases, including cancer and vascular disorders, underpin the demand for embolotherapy as an effective, targeted intervention. Strategic collaborations between healthcare providers and manufacturers also support market growth by fostering innovation and making advanced solutions more accessible globally, especially in emerging markets. Together, these factors are positioning embolotherapy for sustained growth, driven by innovation, expanding applications, and a shift towards precision and minimally invasive treatments in modern healthcare.

Report Scope

The report analyzes the Embolotherapy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Product Segment (Embolic Agents, Support Devices); Disease Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders, Gastrointestinal Disorders).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Embolic Agents segment, which is expected to reach US$4.1 Billion by 2032 with a CAGR of 7.6%. The Support Devices segment is also set to grow at 5.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.0 Billion in 2025, and China, forecasted to grow at an impressive 11.3% CAGR to reach $1.3 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Embolotherapy Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Embolotherapy Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Embolotherapy Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, Acandis GmbH, Balt Extrusion, Boston Scientific Corporation, BTG PLC and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Embolotherapy market report include:

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 5,652 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Global Economic Update
  • Embolotherapy - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Cancer and Vascular Disorders Expands the Addressable Market for Minimally Invasive Embolotherapy Solutions
  • Increasing Adoption of Minimally Invasive Medical Interventions Spurs Growth in Embolotherapy Techniques Across Key Healthcare Markets
  • Technological Advancements in Embolic Agents Improve Precision and Effectiveness, Driving Broader Adoption of Embolotherapy Solutions
  • Expanding Geriatric Population with Increased Risk of Vascular and Cancer-Related Conditions Propels Market Demand for Embolotherapy Procedures
  • Growing Awareness of Uterine Fibroid Embolization as a Non-Surgical Alternative to Hysterectomy Strengthens the Market for Womens Health Applications
  • Rising Prevalence of Arteriovenous Malformations (AVMs) Drives the Need for Specialized Embolotherapy Solutions to Treat Complex Vascular Malformations
  • Shift Toward Outpatient and Ambulatory Care Settings for Embolotherapy Procedures Expands Access and Drives Cost-Effective Healthcare Delivery
  • Growing Use of Embolization Techniques as Less Invasive Alternatives to Open Surgery in Trauma Cases Boosts Demand for Specialized Embolotherapy Solutions
  • Improved Biocompatibility of Next-Generation Embolic Materials Expands Usage in Multi-Therapeutic Applications, Including Oncology and Gynecology
  • Innovations in Catheter Technologies and Delivery Systems Improve Precision and Safety of Embolotherapy Procedures, Supporting Market Growth
  • Increased Adoption of Drug-Eluting Beads in Embolotherapy Enhances Efficacy in Cancer Treatment, Creating New Growth Opportunities in Oncology
  • Rising Global Healthcare Expenditures and Improved Access to Quality Care Drive Demand for Embolotherapy Solutions in Developed and Emerging Markets
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 2: World Historic Review for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 3: World 13-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 4: World Recent Past, Current & Future Analysis for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 5: World Historic Review for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 6: World 13-Year Perspective for Embolic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 7: World Recent Past, Current & Future Analysis for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 8: World Historic Review for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 9: World 13-Year Perspective for Support Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 12: World 13-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 13: World Recent Past, Current & Future Analysis for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 14: World Historic Review for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 15: World 13-Year Perspective for Peripheral Vascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 16: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 17: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 18: World 13-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 19: World Recent Past, Current & Future Analysis for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 20: World Historic Review for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 21: World 13-Year Perspective for Urological & Nephrological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 22: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 23: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 24: World 13-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 25: World Embolotherapy Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
III. MARKET ANALYSIS
UNITED STATES
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 27: USA Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: USA 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 29: USA Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 30: USA Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: USA 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
CANADA
  • Table 32: Canada Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 33: Canada Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: Canada 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 35: Canada Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 36: Canada Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: Canada 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
JAPAN
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 38: Japan Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 39: Japan Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 40: Japan 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 41: Japan Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 42: Japan Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 43: Japan 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
CHINA
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 44: China Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 45: China Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 46: China 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 47: China Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 48: China Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 49: China 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
EUROPE
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 50: Europe Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 53: Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 54: Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 55: Europe 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 56: Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 57: Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 58: Europe 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
FRANCE
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 59: France Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 60: France Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 61: France 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 62: France Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 63: France Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 64: France 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
GERMANY
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 65: Germany Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 66: Germany Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 67: Germany 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 68: Germany Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 69: Germany Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 70: Germany 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
ITALY
  • Table 71: Italy Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 72: Italy Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 73: Italy 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 74: Italy Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 75: Italy Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 76: Italy 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 77: UK Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 78: UK Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 79: UK 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 80: UK Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 81: UK Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 82: UK 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
SPAIN
  • Table 83: Spain Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 84: Spain Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 85: Spain 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 86: Spain Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 87: Spain Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 88: Spain 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
RUSSIA
  • Table 89: Russia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 90: Russia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 91: Russia 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 92: Russia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 93: Russia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 94: Russia 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 96: Rest of Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 97: Rest of Europe 13-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2020, 2026 & 2032
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 99: Rest of Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 100: Rest of Europe 13-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2020, 2026 & 2032
AUSTRALIA
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
  • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

Table Information